Abstract: A display unit displays a display screen including information on injection molding, and the display screen displays a setting screen portion that displays setting contents of the injection molding and a power screen portion that displays information on power consumption of the injection molding based on the setting contents together.

Abstract: A display unit displays a display screen including information on injection molding, and the display screen displays an actual result information display field that displays actual result information on power consumption measured at a time of performing the injection molding and a comparative information display field that displays comparative information on power consumption of the injection molding to be compared with the actual result information on the power consumption in the same display form as a display form of the actual result information display field together.

Abstract: Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer. A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.

Abstract: Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer. A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Abstract: A vehicle radar device provided with a transmission and reception unit for generating a beat signal from a transmission signal and a reception signal, a frequency analysis unit for generating a two-dimensional spectrum including a speed component and a distance component by applying prescribed frequency analysis processing to a signal sequence of the beat signal, and a speed determination unit for dividing the speed component of the two-dimensional spectrum into a plurality of blocks, carrying out constant false alarm rate (CFAR) processing on each of the plurality of blocks, and specifying the speed of the vehicle of the radar device on the basis of a threshold obtained through the CFAR processing.

Abstract: A vehicle radar device provided with a transmission and reception unit for generating a beat signal from a transmission signal and a reception signal, a frequency analysis unit for generating a two-dimensional spectrum including a speed component and a distance component by applying prescribed frequency analysis processing to a signal sequence of the beat signal, and a speed determination unit for dividing the speed component of the two-dimensional spectrum into a plurality of blocks, carrying out constant false alarm rate (CFAR) processing on each of the plurality of blocks, and specifying the speed of the vehicle of the radar device on the basis of a threshold obtained through the CFAR processing.

Abstract: A mount adapter (100, 200) for mounting a display device (D) on a vehicular rearview mirror (R) is configured such that a convex mirror (160, 260) is disposed on the opposite side of the rearview mirror (R) to the driver's seat side when viewed from the driver's seat, with the display device (D) mounted on the driver's seat side of the rearview mirror (R) in such a manner as to cover the rearview mirror (R).

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Abstract: Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer. A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.